Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Net Cash Flow (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Net Cash Flow for 11 consecutive years, with $79.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow changed N/A to $79.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $203.3 million, a N/A change, with the full-year FY2025 number at $178.5 million, up 674.53% from a year prior.
  • Net Cash Flow was $79.9 million for Q4 2025 at Crescent Biopharma, down from $128.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $128.4 million in Q2 2025 to a low of -$16.9 million in Q3 2021.
  • A 5-year average of $5.8 million and a median of -$8.3 million in 2022 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: tumbled 201.0% in 2022, then surged 224.7% in 2023.
  • Crescent Biopharma's Net Cash Flow stood at -$11.7 million in 2021, then skyrocketed by 32.2% to -$7.9 million in 2022, then increased by 3.75% to -$7.6 million in 2023, then crashed by 38.04% to -$10.5 million in 2024, then soared by 860.46% to $79.9 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Net Cash Flow are $79.9 million (Q4 2025), $128.4 million (Q2 2025), and -$5.1 million (Q1 2025).